vs
MESA LABORATORIES INC（MLAB）とStellar Bancorp, Inc.（STEL）の財務データ比較。上の社名をクリックして会社を切り替えられます
Stellar Bancorp, Inc.の直近四半期売上が大きい（$108.9M vs $65.1M、MESA LABORATORIES INCの約1.7倍）。Stellar Bancorp, Inc.の純利益率が高く（24.0% vs 5.6%、差は18.4%）。MESA LABORATORIES INCの前年同期比売上増加率が高い（3.6% vs 0.8%）。Stellar Bancorp, Inc.の直近四半期フリーキャッシュフローが多い（$92.6M vs $18.0M）。過去8四半期でMESA LABORATORIES INCの売上複合成長率が高い（5.1% vs 0.2%）
メサラボラトリーズ社は、品質管理、校正、モニタリング向け専門機器及び関連サービスの開発・製造・販売を事業としています。医療、製薬、食品飲料、産業衛生、環境試験分野を中心に、世界中の顧客の規制遵守と運用安全のニーズに応えています。
Stellar Bancorp, Inc.は米国に本拠を置く金融持株会社で、完全子会社の銀行を通じて事業を展開しています。預金商品、個人・法人向けローン、住宅ローン、資産運用ソリューションなどの小売・商業銀行サービスを幅広く提供し、個人消費者、中小企業、地域の法人顧客に対応しています。
MLAB vs STEL — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $65.1M | $108.9M |
| 純利益 | $3.6M | $26.1M |
| 粗利率 | 64.2% | — |
| 営業利益率 | 12.2% | 29.0% |
| 純利益率 | 5.6% | 24.0% |
| 売上前年比 | 3.6% | 0.8% |
| 純利益前年比 | 316.6% | 3.7% |
| EPS（希薄化後） | $0.65 | $0.52 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $65.1M | $108.9M | ||
| Q3 25 | $60.7M | $105.6M | ||
| Q2 25 | $59.5M | $104.1M | ||
| Q1 25 | $62.1M | $104.8M | ||
| Q4 24 | $62.8M | $108.0M | ||
| Q3 24 | $57.8M | $107.8M | ||
| Q2 24 | $58.2M | $106.8M | ||
| Q1 24 | $58.9M | $108.4M |
| Q4 25 | $3.6M | $26.1M | ||
| Q3 25 | $2.5M | $25.7M | ||
| Q2 25 | $4.7M | $26.4M | ||
| Q1 25 | $-7.1M | $24.7M | ||
| Q4 24 | $-1.7M | $25.2M | ||
| Q3 24 | $3.4M | $33.9M | ||
| Q2 24 | $3.4M | $29.8M | ||
| Q1 24 | $-254.6M | $26.1M |
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | — | ||
| Q2 25 | 62.0% | — | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 64.0% | — | ||
| Q1 24 | 62.1% | — |
| Q4 25 | 12.2% | 29.0% | ||
| Q3 25 | 7.8% | 30.5% | ||
| Q2 25 | 5.1% | 31.7% | ||
| Q1 25 | 2.4% | 29.6% | ||
| Q4 24 | 9.2% | 29.4% | ||
| Q3 24 | 6.1% | 39.6% | ||
| Q2 24 | 9.6% | 35.1% | ||
| Q1 24 | -460.6% | 30.4% |
| Q4 25 | 5.6% | 24.0% | ||
| Q3 25 | 4.1% | 24.3% | ||
| Q2 25 | 8.0% | 25.3% | ||
| Q1 25 | -11.4% | 23.6% | ||
| Q4 24 | -2.7% | 23.3% | ||
| Q3 24 | 5.9% | 31.4% | ||
| Q2 24 | 5.8% | 27.9% | ||
| Q1 24 | -432.2% | 24.1% |
| Q4 25 | $0.65 | $0.52 | ||
| Q3 25 | $0.45 | $0.50 | ||
| Q2 25 | $0.85 | $0.51 | ||
| Q1 25 | $-1.30 | $0.46 | ||
| Q4 24 | $-0.31 | $0.47 | ||
| Q3 24 | $0.63 | $0.63 | ||
| Q2 24 | $0.62 | $0.56 | ||
| Q1 24 | $-47.26 | $0.49 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $29.0M | $419.5M |
| 総負債低いほど良い | $68.4M | — |
| 株主資本純資産 | $186.7M | $1.7B |
| 総資産 | $434.8M | $10.8B |
| 負債/資本比率低いほどレバレッジが低い | 0.37× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $29.0M | $419.5M | ||
| Q3 25 | $20.4M | $728.4M | ||
| Q2 25 | $21.3M | $578.1M | ||
| Q1 25 | $27.3M | $560.6M | ||
| Q4 24 | $27.3M | $911.2M | ||
| Q3 24 | $24.3M | $516.2M | ||
| Q2 24 | $28.5M | $490.3M | ||
| Q1 24 | $28.2M | $399.7M |
| Q4 25 | $68.4M | — | ||
| Q3 25 | $69.4M | — | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | — | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $186.7M | $1.7B | ||
| Q3 25 | $178.5M | $1.7B | ||
| Q2 25 | $172.5M | $1.6B | ||
| Q1 25 | $159.8M | $1.6B | ||
| Q4 24 | $155.2M | $1.6B | ||
| Q3 24 | $161.5M | $1.6B | ||
| Q2 24 | $150.7M | $1.6B | ||
| Q1 24 | $145.4M | $1.5B |
| Q4 25 | $434.8M | $10.8B | ||
| Q3 25 | $430.4M | $10.6B | ||
| Q2 25 | $435.7M | $10.5B | ||
| Q1 25 | $433.3M | $10.4B | ||
| Q4 24 | $433.3M | $10.9B | ||
| Q3 24 | $454.1M | $10.6B | ||
| Q2 24 | $440.4M | $10.7B | ||
| Q1 24 | $446.8M | $10.7B |
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $18.8M | $97.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $18.0M | $92.6M |
| FCFマージンFCF / 売上 | 27.7% | 85.0% |
| 設備投資強度設備投資 / 売上 | 1.1% | 4.0% |
| キャッシュ転換率営業CF / 純利益 | 5.17× | 3.71× |
| 直近12ヶ月FCF直近4四半期 | $37.9M | $173.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $18.8M | $97.0M | ||
| Q3 25 | $8.2M | $63.6M | ||
| Q2 25 | $1.9M | $25.8M | ||
| Q1 25 | $12.7M | $-5.7M | ||
| Q4 24 | $18.1M | $132.6M | ||
| Q3 24 | $5.3M | $59.5M | ||
| Q2 24 | $10.7M | $38.1M | ||
| Q1 24 | $12.9M | $31.1M |
| Q4 25 | $18.0M | $92.6M | ||
| Q3 25 | $7.1M | $62.5M | ||
| Q2 25 | $884.0K | $24.5M | ||
| Q1 25 | $11.9M | $-6.4M | ||
| Q4 24 | $17.3M | $128.0M | ||
| Q3 24 | $3.5M | $57.7M | ||
| Q2 24 | $9.9M | $37.1M | ||
| Q1 24 | $12.3M | $30.5M |
| Q4 25 | 27.7% | 85.0% | ||
| Q3 25 | 11.7% | 59.2% | ||
| Q2 25 | 1.5% | 23.6% | ||
| Q1 25 | 19.2% | -6.2% | ||
| Q4 24 | 27.6% | 118.5% | ||
| Q3 24 | 6.0% | 53.5% | ||
| Q2 24 | 16.9% | 34.8% | ||
| Q1 24 | 21.0% | 28.2% |
| Q4 25 | 1.1% | 4.0% | ||
| Q3 25 | 1.8% | 1.1% | ||
| Q2 25 | 1.7% | 1.2% | ||
| Q1 25 | 1.2% | 0.7% | ||
| Q4 24 | 1.3% | 4.3% | ||
| Q3 24 | 3.1% | 1.7% | ||
| Q2 24 | 1.5% | 0.9% | ||
| Q1 24 | 0.9% | 0.5% |
| Q4 25 | 5.17× | 3.71× | ||
| Q3 25 | 3.32× | 2.48× | ||
| Q2 25 | 0.40× | 0.98× | ||
| Q1 25 | — | -0.23× | ||
| Q4 24 | — | 5.26× | ||
| Q3 24 | 1.54× | 1.76× | ||
| Q2 24 | 3.17× | 1.28× | ||
| Q1 24 | — | 1.19× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
STEL
セグメントデータなし
